The premise
Why the follicle is the right target
HS does not begin in the skin generally. It begins at the follicle — the opening becomes occluded, the follicle ruptures into the surrounding tissue, and the immune system responds with the inflammation that produces the nodules and abscesses patients feel. Every other feature of HS — drainage, scarring, sinus tracts — follows from that initiating event.
Multiple randomized trials have shown that long-pulsed laser therapy directed at the affected follicles reduces lesion counts and slows progression in HS. The benefit is reproducible across studies, not a single-center observation. This is the mechanistic reason follicle therapy is part of our protocol rather than a marketing claim.
Important caveat: this works on inflammatory disease. Once the follicle has ruptured repeatedly and organized into a sinus tract, the structural problem is no longer in the follicle — it is in the tract — and a different tool is required.
Mechanism
How the device works
The laser most commonly used for HS is a long-pulsed Nd:YAG at 1064 nm. Alexandrite (755 nm) and diode (810 nm) devices are alternatives in selected skin types. All three deliver energy that is preferentially absorbed by melanin in the hair follicle, generating heat that damages the follicular unit while sparing surrounding skin — the principle of selective photothermolysis.
Pulse duration and wavelength matter. A longer pulse delivers energy slowly enough to confine damage to the follicle; the 1064 nm wavelength penetrates deeply enough to reach follicles in thicker intertriginous skin and is the safest choice across darker Fitzpatrick skin types, where shorter wavelengths risk pigmentary change.
Indications
Who it's for
Hurley stage I
Primary indication. Inflammatory disease without established tracts — exactly the population the literature supports most strongly. Most Hurley I patients can expect meaningful flare reduction with a full course.
Hurley stage II (selected)
Used when active inflammation is the dominant feature, when tracts are limited, or as part of a sequenced plan in which follicle therapy precedes or follows CO₂ closure.
Pre-procedural use
Some patients planned for CO₂ tunnel closure benefit from a short course of follicle therapy first, to quiet the inflammatory field around the area we intend to operate on.
Non-indications
Who it is not for
- Patients with extensive established sinus tracts where the dominant problem is structural — CO₂ tunnel closure is the right tool.
- Patients whose medical regimen has not been optimized. If dermatology has not yet had a fair turn, we ask them to lead first.
- Active infection in the planned treatment field — we defer until it resolves.
- Patients seeking a one-time cure. The model is sequenced and assumes ongoing medical co-management.
What to expect
The treatment course
Consultation and mapping
We define which regions to treat, document the disease photographically, and set the baseline against which response will be measured.
Sessions
Typically 4–6 office-based sessions, spaced 4–6 weeks apart. Total course runs about 4–6 months.
Each visit
Brief clinical exam, photographic documentation, treatment delivery (20–45 minutes depending on area), and written aftercare. Topical cooling and short-acting numbing if helpful. No general anesthesia; you drive yourself home.
Reassessment
At session 4 we formally reassess. Many patients are on track and finish the course; some need maintenance sessions; some transition to CO₂ closure for residual tracts; some we decide are not responding and change course honestly.
Realistic outcomes
What response looks like — and what it doesn't
Most patients begin to notice a difference around sessions two or three. Full benefit is assessed three to six months after the course completes, once the follicular biology has fully reorganized.
"Working" means fewer flares per quarter, smaller flares when they occur, less drainage, and slower progression toward tract formation. It does not mean zero flares, and it does not mean closure of tracts that already exist — those are structural disease and require CO₂ closure.
If at session four there is no measurable improvement, we reassess. The options on the table are escalation to CO₂ closure for tracts we may have under-appreciated, a change in the medical regimen alongside dermatology, or — when appropriate — referral to a different team. Continuing a course that is not working is not a service to the patient.
Risks & limits
Risks, side effects, and limits
- Transient redness, mild swelling, and tenderness. Typical for 24–72 hours after a session and self-resolving.
- Pigmentary change. Hyper- or hypopigmentation, more likely in darker Fitzpatrick skin types. Risk is mitigated by device selection and conservative settings.
- Folliculitis-like reaction. Occasional, transient, managed with topical care.
- Burns or blistering. Rare with appropriate device choice and settings; risk is operator-dependent.
- Failure to respond. A real outcome we name explicitly. Roughly assessed at session four; we change course rather than continue indefinitely.
- Not a cure, not a replacement for medical therapy. Follicle therapy works alongside your dermatologist's plan, not instead of it.
An important distinction
How this is different from cosmetic laser hair removal
The device class is the same. The intent is not. Cosmetic laser hair removal targets aesthetic reduction across normal skin, on a schedule built around appearance. Follicle therapy for HS targets diseased follicles in inflammatory skin, on a schedule built around disease activity, with photographic documentation tied to a treatment plan that includes escalation pathways.
The operator matters. The willingness to reassess at session four, to escalate to CO₂ closure when tracts reveal themselves, and to coordinate with dermatology — none of that is part of a med-spa visit. It is the reason this is a medical procedure and not a cosmetic one.
Sequencing
Where this fits with medical therapy and CO₂ closure
Follicle therapy is complementary to systemic medical therapy, not a substitute. Patients on biologics typically continue them through the course; we coordinate with the prescribing physician.
Follicle therapy and CO₂ closure address different dimensions of the same disease — inflammation versus structure. Many of our patients receive both, in sequence determined by which problem dominates.
Read about CO₂ tunnel closure →Read the full treatment model →